Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease-Reference-Cited by-同舟云学术

Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease

Published:2018-02-16 Issue:3 Volume:24 Page:601-606
ISSN:1078-0998
Container-title:Inflammatory Bowel Diseases
language:en
Short-container-title:

Author:

Fiorino Gionata¹,Ruiz-Argüello M Begoña²,Maguregui Ainara²,Nagore Daniel²,Correale Carmen¹,Radice Simona¹,Gilardi Daniela¹,Allocca Mariangela¹,Furfaro Federica¹,Martínez Antonio²,Danese Silvio¹³

Affiliation:

1. IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy

2. R&D Department, Progenika Biopharma SA, Derio, Spain

3. Department of Biomedical Sciences, Humanitas University, Rozzano, Milan, Italy

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,Immunology and Allergy

Link

http://academic.oup.com/ibdjournal/article-pdf/24/3/601/24250571/izx086.pdf

Reference23 articles.

1. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases;Braun;Immunotherapy,2015